Pembrolizumab for thymus cancer that cannot be removed
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies pembrolizumab, an immunotherapy medicine, in people with thymoma or thymic cancer that cannot be removed with surgery. It aims to see how well the treatment works and how safe it is, including whether your immune system can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your thymus tumor must be thymoma or thymic cancer that cannot be removed by surgery.
- You must have a measurable tumor on scans, and be able to start treatment with recently measurable disease.
- You must be able to sign consent (or assent, if needed) to join the study.
- You must be able to provide a new tumor tissue sample (biopsy) within about 6 weeks of starting treatment, or provide an older stored sample if a new one isn’t possible.
- Your overall health must be fairly strong (ECOG performance status 0 or 1).
- You must have adequate blood counts and organ function based on recent lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a first (initial) treatment combination of pembrolizumab with three other drugs (carboplatin, paclitaxel, and lenvatinib) for advanced or recurrent thymic carcinoma. It aims to shrink tumors and improve control of the cancer when standard chemotherapy has not yet been tried for your situation.
This study tests pembrolizumab (an immune therapy) in people with high-risk thyroid cancer that is hard to treat with surgery alone. It looks at whether this drug can reduce persistent or recurrent cancer after your planned treatment.
This trial tests pembrolizumab (an immunotherapy that helps the body recognize and attack cancer) in children with advanced solid tumors or lymphoma that can’t be cured. It’s designed for kids who have already tried standard treatments or don’t have standard treatment options.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial tests a drug called pembrolizumab (Keytruda) to see if it helps people with several types of cancer, including relapsed or refractory lymphoma, melanoma, MSI-high or TMB-high solid tumors, and Merkel cell carcinoma. The goal is to understand if this immunotherapy can shrink or control the cancer.
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
Hear when a new Stage III Thymoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.